Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)88

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)24

Views

Views
July 20254
August 20250
September 20250
October 20251
November 20252
December 202517
January 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil11
United Kingdom4
Argentina1
Germany1
Denmark1
Algeria1
Ecuador1
Netherlands1
Turkey1
United States1
 

Top cities views

Views
Algiers1
Beckenham1
Brasília1
Camaçari1
Campo Grande1
Canoas1
Comodoro Rivadavia1
Durban1
Fortaleza1
Goioerê1